Use of kv1.3 blockers for inflammatory skin conditions

W. Nguyen, B. L. Howard, D. S. Neale, P. E. Thompson, P. J. White, Heike Wulff, D. T. Manallack

Research output: Contribution to journalArticlepeer-review

15 Scopus citations


Recent results using animal models of inflammatory skin conditions have shown that blockers of the voltage-gated potassium channel, Kv1.3 hold great promise for clinical utility. Kv1.3 blockers act as immunosuppressants by modulating the various subsets of inflammatory T and B cells involved in autoimmune disorders. While peptidic inhibitors based on naturally occurring venoms demonstrate potent and selective Kv1.3 blockade, these require parenteral administration and may face potential immunogenicity problems. Small molecule blockers show considerable diversity, however selectivity over other Kv1-family channels has been difficult to achieve. More recent advances have added to the evidence that Kv1.3 channels are a suitable therapeutic target and that the development of novel and selective agents will herald new drugs for inflammatory skin disorders.

Original languageEnglish (US)
Pages (from-to)2882-2896
Number of pages15
JournalCurrent Medicinal Chemistry
Issue number26
StatePublished - 2010


  • Autoimmune disorder
  • Drug design
  • Inflammation
  • Kv1.3 channel
  • Psoriasis

ASJC Scopus subject areas

  • Molecular Medicine
  • Pharmacology


Dive into the research topics of 'Use of kv1.3 blockers for inflammatory skin conditions'. Together they form a unique fingerprint.

Cite this